ArticleJournal of cancer research and practice
Impact of COVID-19 on Timeliness of Receiving Systemic Therapy for Patients Diagnosed with Lung Cancer.
Article in Journal of cancer research and practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive patient navigation is associated with increased active treatment retention in lung cancer care in rural Appalachia.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: During the COVID-19 pandemic, patients newly diagnosed with lung cancer faced potential delays in accessing timely cancer treatment. Little information exists on how COVID-19 impacted the timeliness of receiving a first course of systemic therapy after a lung cancer diagnosis. Materials and Methods: Data from the Population-based Research to Optimize the Screening Process-Lung Consortium were used to identify patients diagnosed with Stage I to IV lung cancer between January 1, 2018 and September 30, 2021, for this retrospective cohort study. The patients were categorized into three groups based on the date of diagnosis: pre-COVID-19 (January 1, 2018-March 14, 2020), early COVID-19 (March 15, 2020-June 30, 2020), and late COVID-19 (July 1, 2020-September 30, 2021). We explored changes in the time from cancer diagnosis to initiation of the first course of systemic therapy using interrupted time series (ITS) analysis across the pre-, early, and late COVID-19 time periods. Results: We identified 810 patients with lung cancer who received a first course of systemic therapy during the study period. The average number of patients diagnosed with lung cancer per month decreased from 17.0 in the pre-COVID-19 period to 15.3 in the early COVID-19 period and then increased to 19.3 in the late COVID-19 period. ITS models estimated a 9.6-day increase (95% confidence interval: 4.8, 14.5; Conclusion: Our findings indicate a delay in initiating systemic therapy among patients with lung cancer during the early COVID-19 period compared to the pre- and late COVID-19 periods; however, the time to initiating treatment recovered quickly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.